The drug "Gliadab MB": instructions for use, reviews

For maintenance treatment of the second type of diabetes sugar, in which insulin molecules are produced, glycazide-based drugs are used. This substance is a sulfonylurea derivative, belonging to the second generation.

general characteristics

The drug "Glidiab MB 30" is considered a Russian analogue of the French drug "Diabeton MV". It is produced by the chemical-pharmaceutical combine "Akrihin" in the Moscow region.

Medication refers to oral hypoglycemic agents in a tablet form having a modified release. The color of their structure is white or cream, there may be marbled impregnations. Tablets resemble flat cylinders, which have a facet.

Consumer packaging is a bundle. It can contain 30 or 60 tablets, packaged on blister plates.

Composition

Unlike the drug Diabetes MW with a dose of 0.060 g of gliclazide, the amount of identical active ingredient in Gliadab MB is two times lower, which is 0.030 g.

Inactive tabletting components include hydroxypropylmethylcellulose, aerosil molecules, magnesium stearate, microcrystalline cellulose.

There is also a drug "Glydiab" with the usual release of the active substance. The dosage in one tablet is 0.08 g of gliclazide.

How it works

The Glydiab MB application kit describes the action of Gliclazide, which stimulates the secretion of insulin in β-cells located in the pancreas.

Under the influence of tablets, the insulin secretory activity of glucose molecules increases, and peripheral tissues become more sensitive to insulin hormone.

Muscle glycogen synthetase, being an intracellular enzyme, is more effective. There is a decrease in the interval from the beginning of eating before the release of the hormone. Insulin secretion is restored at an early peak, which distinguishes gliclazide from the remaining sulfonylurea precursors, which occur in the second stage. The postprandial glucose level decreases.

There is an improvement in microcirculation due to pooling and clumping of platelet cells, normalization of the permeability of the vascular wall, reduction in the development of microthrombotic and atherosclerotic processes, restoration of the reactions of natural dissolution of blood clots. The possibility of reacting receptor structures in the vessels to adrenaline molecules decreases.

The drug is able to slow the diabetic nature of retinopathy at the non-proliferative stage. Long-term treatment with this drug in conditions of diabetic damage to the components of the renal parts responsible for the filtration, can significantly reduce the excretion of proteins in the urine.

The drug does not increase the body weight, but on the contrary, it decreases due to the effect on the early stage of insulin secretion. It does not provoke increased insulinemia.

Why use

Doctors recommend using the drug with high sugar in the blood of the second degree. Treatment is carried out with insufficient effect from diet and moderate physical exertion.

For the drug "Glydiab MB" indications are associated with the prevention of deterioration in diabetic disorders, characterized by nephropathy, retinopathy, myocardial infarction and stroke.

How to use

Dosing of the drug is selected for each patient separately, taking into account the manifestations of the disease, glucose concentration with an empty stomach and 120 minutes after eating.

For the drug "Gliadab MB" instructions for use appoint a daily initial dose of 0.03 grams, which is equivalent to one tablet. This concentration is indicated by elderly patients after 65 years of age. The medication is taken orally on a single pill every morning when breakfast is served.

If necessary, the dosage is increased every two weeks. Maximum for one day is allowed to take about 0.120 g, which corresponds to 4 tablets.

The drug "Gliadab MB" is used instead of the same-name medication with the usual release, consuming 1-4 tablets per day.

It is combined with a hypoglycemic agent based on biguanide, retarder of alpha-glucosidase of insulin molecules.

If violations of kidney work are weak or moderate, when the rate of creatinine removal is not more than 0.080 l per minute, dosing is not reduced.

When you can not take

Glydiab MB tablets do not recommend using the first form of diabetes mellitus, with ketones in the urine, gastric paresis, hyperosmolar, diabetic coma and precoma, with large surgical operations and burn lesions, traumatic processes when insulin is needed treatment.

Contraindications are severe violations of liver or kidney function, intestinal obstruction, changes in food assimilation, development of hypoglycemia.

Do not use the drug for fever, leukopenia, pregnancy, breastfeeding and excessive intolerance to the ingredients of the medication.

Care should be taken when administering the drug, special care and the choice of dosage for patients who have alcohol dependence and disorders in the thyroid gland.

Features of treatment

To the medicine "Glidiab MB" instructions for use indicate the need to combine it with a low-calorie diet, which includes a small carbohydrate content. It is necessary to regularly monitor the concentration of glucose in the bloodstream from the morning before and after eating.

If there were surgical interventions or decompensation of the diabetic state, it is possible to administer insulin.

There are warnings about the occurrence of hypoglycemic process with the use of ethyl alcohol, non-steroidal anti-inflammatory substance and lack of nutrition. The use of alcoholic beverages can cause disulfiramoid-like syndrome, while the head and stomach ache, nausea and vomiting are possible.

It is necessary to adjust the dosage of the medication during physical or emotional stress and when eating untimely.
Particularly sensitive to the effect of the remedy are the elderly, patients with unbalanced or poor nutrition, weakened patients who suffer from insufficiency of the adrenal-pituitary system.

At the initial stages of drug use, when choosing a dosage, if there is a predisposition to a hypoglycemic crisis, one does not need to perform actions for which increased attention and a rapid psychomotor reaction are necessary.

Undesirable reactions

The Glidiab MB tool includes information on violations in the endocrine organs in case of failure in the mode of tablet use and in case of malnutrition. Usually, a decrease in the level of glucose in the bloodstream causes the occurrence of pain in the head, tired, hungry, helpless, anxious, instant weakness, aggression, weak concentration, depressive state. Also there are changes in visual perception, tremor, sensory and convulsive disorder, dizziness, hypersomnia, shallow breathing, decreased heart rate.

Digestive organs cause malfunctioning in the form of malabsorption, nausea, diarrhea, anorexic lack of appetite, a disruption in the functioning of liver cells, cholestatic jaundice, and an increase in the effectiveness of transaminase enzymes.

Undesirable processes in the hematopoietic system are associated with a decrease in hemoglobin, the number of platelet and leukocyte cells.

The drug can cause allergic manifestations in the form of itching, urticaria, maculopapular rash.

Excessive introduction

The instructions for use with Glidiab MB are cautions against overdose, which is expressed by a decrease in the glucose concentration in the blood plasma. With a strong excess of the drug, it is possible to develop a hypoglycemic coma.

To eliminate it, people are allowed to eat a little well-sucked hydrocarbons, for example, a piece of sugar. When a person is unconscious, a 40% dextrose or glucose solution is injected into the vein, and 1 mg of glucagon is injected into the muscle. If the patient wakes up, then he is forced to eat well-absorbed hydrocarbons to avoid a repetition of a hypoglycemic attack.

Combination with drugs

The hypoglycemic activity of the drug Gliadiab MB 30 mg can be enhanced by the parallel introduction of a retarder Enzyme angiotensin-converting and monoamine oxidase type, Blocker of receptor formations of beta-adrenoreactive and H2-histamine-dependent cimetidine, antifungal miconazole and fluconazole preparations, non-steroidal anti-inflammatory substances of phenylbutazone, indomethacin, diclofenac.

The effect of tablets is increased with the help of clofibrates and bezafibrates, anti-tuberculosis drugs from the group of ethionamide, salicylates, indirect anticoagulant compounds of the coumarin structure, anabolic steroids, cyclophosphamide, chloramphenicol, sulfonamides with prolonged influence.

The drug effectively reduces sugar in blood plasma, if you use blockers tubular discharge, ethyl alcohol, acarbose, biguanide, insulin.

Decrease in the hypoglycemic effect of the tablets is caused by barbiturates, drugs based on epinephrine, clonidine, terbutaline, ritodrine, salbutamol, phenytoin, retarders of the carbonic anhydrase enzyme such as acetazolamide, thiazide diuretics, thyroid hormones, lithium-containing medications, estrogen remedies.

Molecules of ethyl alcohol are able to affect the glycazide with the emergence of a disulfiram-like process.

The active component of tablets causes untimely depolarization and contraction of the ventricles of the myocardium muscle when combined with cardiac glycosides.

Beta-adrenoblocking agents, clonidine, reserpine, guanetidine drugs mask clinical hypoglycemia.

Patient's opinions

It is important not only the instructions for use attached to the drug Gliadiab MV. Reviews tell us about what patients think about the effectiveness of the drug. This tool helps many patients to reduce the concentration of glucose to normal values, and in combination with the diet changes the way the patient lives.

People note that a positive feature of the tablets is their convenient use in the morning. During the day you can not remember the need for treatment.

On the drug "Glidiab MB" reviews can be heard and negative nature associated with the ineffectiveness of this tool. Usually this is the case with incorrect dosing, when a small amount of medicine is prescribed.